Urinary tract infection

World Hexamine Market Report 2021: CAGR Market Growth of 6.5% Forecast Between 2021-2026, with Market Value of $585.6 Million by 2026

Monday, September 20, 2021 - 8:15pm

DUBLIN, Sept. 20, 2021 /PRNewswire/ -- The "Global Hexamine Market Report and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 20, 2021 /PRNewswire/ -- The "Global Hexamine Market Report and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global hexamine market attained a value of 369.8 USD million in 2020.
  • It has a fishy or ammonia-like odour, has a density of 1.33 g/cm3 (at 20 C) and is highly soluble in water.
  • The market report analyses the market based on segmentations such as grades, applications and major regions.

Olympus Selected To Exhibit iTind Device For BPH Treatment At Vizient Innovative Technology Exchange

Monday, September 20, 2021 - 3:17pm

CENTER VALLEY, Pa., Sept. 20, 2021 /PRNewswire/ -- Olympus has been selected to exhibit the iTind™ device, a temporarily implanted device for relief of enlarged prostate symptoms, at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation's largest member-driven health care performance improvement company, will hold the Exchange virtually September 21-23.

Key Points: 
  • CENTER VALLEY, Pa., Sept. 20, 2021 /PRNewswire/ -- Olympus has been selected to exhibit the iTind device, a temporarily implanted device for relief of enlarged prostate symptoms, at the Vizient Innovative Technology Exchange.
  • "Olympus is thrilled to bring the iTind device to the Vizient Innovative Technology Exchange," said Randy Clark, President of the Olympus Medical Systems Group.
  • The annual Innovative Technology Exchange is part of Vizient's Innovative Technology Program that includes product review of supplier-submitted technologies by member-led councils and task forces.
  • Since 2003, Vizient has received over 2,800 technology submissions as part of its Innovative Technology Program.

SG Blocks to Manufacture Two High-Complexity Mobile CLIA-Certified Laboratories

Monday, September 20, 2021 - 1:30pm

SG Blocks, Inc. (NASDAQ: SGBX) (SG Blocks or the Company), a leading designer, innovator and fabricator of modular structures, announced today that the Company has developed a new modular laboratory product at the SG Echo campus in Durant, Oklahoma and plans to build and deploy mobile intermodal CLIA-certified laboratories for point-of-care healthcare testing.

Key Points: 
  • SG Blocks, Inc. (NASDAQ: SGBX) (SG Blocks or the Company), a leading designer, innovator and fabricator of modular structures, announced today that the Company has developed a new modular laboratory product at the SG Echo campus in Durant, Oklahoma and plans to build and deploy mobile intermodal CLIA-certified laboratories for point-of-care healthcare testing.
  • View the full release here: https://www.businesswire.com/news/home/20210920005326/en/
    High-Complexity Mobile CLIA-Certified Laboratories (Photo: Business Wire)
    SG Blocks will own and operate these units, providing its own end-to-end solution including both staffing and billing.
  • Clients from various industries and sectors such as sports teams, universities, entertainment companies, and more will be targeted to hire SG Blocks to deploy the flexible mobile unit wherever needed.
  • We have seen a great need for adaptable and efficient healthcare testing through our deep-dive into COVID-19 testing, Paul Galvin, Chairman and CEO of SG Blocks explained.

Two PetSafe® Products Honored With Pet Independent Innovation Awards

Monday, September 20, 2021 - 12:00pm

KNOXVILLE, Tenn., Sept. 20, 2021 /PRNewswire/ --PetSafe brand, a global leader in pet product solutions, was recently honored with two 2021 Pet Independent Innovation Awards, which recognize the innovators and leaders of the pet industry.

Key Points: 
  • KNOXVILLE, Tenn., Sept. 20, 2021 /PRNewswire/ --PetSafe brand, a global leader in pet product solutions, was recently honored with two 2021 Pet Independent Innovation Awards, which recognize the innovators and leaders of the pet industry.
  • With more than 1,250 nominations coming in from all over the world for the 2021 Pet Independent Innovation Awards , the products were assessed on innovation, performance, ease of use, functionality, impact, value and more.
  • "It is an honor to receive this recognition from the Pet Independent Innovation Awards because it showcases the PetSafe team's commitment to keeping pets healthy, safe, and happy through our innovative and thoughtful product design," says Celeste Vlok, marketing manager for PetSafe brand.
  • The PetSafe ScoopFree Smart Self-Cleaning Litter Box automatically rakes away cat waste to eliminate scooping, cleaning, and refilling for weeks.

ITRM BREAKING NOTICE: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Iterum Therapeutics plc Investors with Losses to Secure Counsel Before Important October 4 Deadline in Securities Class Action – ITRM

Saturday, September 18, 2021 - 12:30am

WHAT TO DO NEXT: To join the Iterum class action, go to http://www.rosenlegal.com/cases-register-2142.html or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Iterum class action, go to http://www.rosenlegal.com/cases-register-2142.html or call Phillip Kim, Esq.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Global Hexamine Market Outlook and Forecast 2021-2026: Rising Demand for Agrochemicals Fuels Demand as Hexamine is Key Raw Material - ResearchAndMarkets.com

Friday, September 17, 2021 - 12:55pm

The "Global Hexamine Market Report and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Hexamine Market Report and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global hexamine market attained a value of 369.8 USD million in 2020.
  • The market will be driven by the rising demand for agrochemicals such as herbicides, fungicides and insecticides, as hexamine is key raw material in their production.
  • The market in the region is driven by the rising demand for hexamine as a food preservative in the food and beverage industry.

Hims & Hers Expands Women’s Health Offerings With Support For Urinary Tract Health

Thursday, September 16, 2021 - 1:57pm

Hims & Hers Health, Inc. (Hims & Hers, NYSE: HIMS), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers, recently expanded its womens health offerings with the recent launch of a D-Mannose dietary supplement powder to support urinary tract health on ForHers.com .

Key Points: 
  • Hims & Hers Health, Inc. (Hims & Hers, NYSE: HIMS), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers, recently expanded its womens health offerings with the recent launch of a D-Mannose dietary supplement powder to support urinary tract health on ForHers.com .
  • Roughly 3 or 4 in 10 women who experience an initial urinary tract infection (UTI) will face another one within six months.
  • Theres a clear need for ways to be proactive about urinary tract health, said Hilary Coles, co-founder and SVP of Brand & Innovation, Hims & Hers.
  • Launched in November 2017, the company also offers thoughtfully created and curated health and wellness products.

Spero Therapeutics to Present Data at IDWeek 2021

Thursday, September 16, 2021 - 1:05pm

CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced 23 data presentations at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 October 3, 2021.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced 23 data presentations at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 October 3, 2021.
  • Title: Molecular epidemiology of Escherichia coli causingurinary tract infectionsin the United States and in vitro activity of tebipenem, includingagainststrain lineage and resistant subsets (2018-2020)
    12.
  • Title: An evaluation of tebipenem in vitro activity against a panel of Pseudomonas aeruginosa isolates with Efflux, AmpC, and OprD Mutations
    14.
  • InSeptember 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.

New Data Demonstrate Trodelvy® Survival Benefit in Metastatic Triple-Negative Breast Cancer Patients Regardless of Initial HR/HER2 Status

Thursday, September 16, 2021 - 12:00pm

Trodelvy is already transforming outcomes for patients with second-line or later metastatic TNBC, said Bill Grossman, MD, PhD, Senior Vice President, Oncology Clinical Research, Gilead Sciences.

Key Points: 
  • Trodelvy is already transforming outcomes for patients with second-line or later metastatic TNBC, said Bill Grossman, MD, PhD, Senior Vice President, Oncology Clinical Research, Gilead Sciences.
  • TNBC is the most aggressive type of breast cancer and accounts for approximately 15% of all breast cancers.
  • Among women with metastatic TNBC, the five-year survival rate is 12%, compared with 28% for those with other types of metastatic breast cancer.
  • Trodelvy is also being investigated as a potential treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer and metastatic non-small cell lung cancer.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Iterum Therapeutics plc of Class Action Lawsuit and Upcoming Deadline – ITRM

Thursday, September 16, 2021 - 2:17am

NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Iterum Therapeutics plc (Iterum or the Company) (NASDAQ: ITRM) and certain of its officers.

Key Points: 
  • NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Iterum Therapeutics plc (Iterum or the Company) (NASDAQ: ITRM) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Iterum is a clinical-stage pharmaceutical company that engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.